We are pleased to present our 2021 Year in Review, showcasing the important progress we’ve made in the fight against Alzheimer’s disease over the last year
right here in Massachusetts and New Hampshire. Our staff, community partners, volunteers, and public policy advocates have worked tirelessly to support the 156,000 individuals living with this disease across our two states.
We are pleased to present our 2021 Year in Review, showcasing the important progress we’ve made in the fight against Alzheimer’s disease and all other dementia. Our staff, community partners, volunteers, and public policy advocates have worked tirelessly to support the 156,000 individuals living with this disease across our two states.
Even with some of the COVID-related challenges of the past year, we are pleased to have provided uninterrupted care and support services for our constituents. While many of our staff are still working remotely, we look forward to actively engaging with our communities. We also anticipate reopening offices in Bedford, NH and Worcester, MA in 2022.
Due to the pandemic we continue to deliver most of our education programs, support groups, and early-stage engagement programs virtually, but we are increasing the number of in-person offerings each month. Over the past year 30,000 people accessed the full range of our programs and services, delivered at no cost to families.
This year, our generous supporters helped us raise more than $13 million to continue funding research and care and support programs in local communities across our two states. Our advocacy efforts resulted in increased federal funding for research and improved quality of care in both nursing homes and community settings.
We continue to expand our diversity and inclusion efforts, reaching into new communities and strengthening our volunteer base, while expanding our awareness activities into underserved communities to reach high-risk populations. We are forging new partnerships with community leaders and grassroots organizations, with a focus on six key areas of opportunity: Boston, Springfield, Worcester, Brockton, New Bedford and Manchester, NH.
We have over $19 million in active funding awarded to local researchers through our International Research Grants Program, ensuring that we will continue to have an impact on the quest for an effective treatment for this devastating disease.
And finally, in June the FDA announced its approval of aducanumab (Aduhelm), the first disease-modifying treatment for those in the early stages of Alzheimer’s disease. While not a cure, this new therapy could mean more time for individuals to actively participate in daily life, have sustained independence and hold on to memories longer. And, there are more than 60 phase-three dementia clinical trials underway, providing hope for further advancement.
All of this wouldn’t be possible without you, and we are tremendously grateful for your continued support.
Jean Morse Jones, Chair, Board of Directors
James Wessler, CEO, MA/NH Chapter and New England Regional Leader